Unilateral Bevacizumab for Bilateral Diabetic Macular Edema

Sponsor
Asociación para Evitar la Ceguera en México
Study ID
NCT00496405
Phase
PHASE4
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The endothelial growth factor (VEGF), has been implied in the genesis of diverse Neovascular disease. In the industrialized and developing countries, the main cause of blindness is the diabetic retinopathy. Bevacizumab (Avastin, genentech, Inc., San Francisco, California, the USA) is a drug.In the last years its use "off-label", in ophthalmology field, has become popular. This is due to its proven safeness and effectiveness for the treatment of diverse ocular diseases. A lot has been speculated about the systemic absorption of Bevacizumab. It is for that reason that the objective of this study is the systematic and random revision of the fellows eyes, of the patients programmed for the intravitreal administration of Bevacizumab, with bilateral macular edema. In such a way that the therapeutic value in the fellow eye of bevacizumab can be determined

Key Dates

First listed
Jul 4, 2007
Start date
Apr 30, 2007
Status verified
Jun 2024
Completion
Oct 31, 2007

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
PARALLEL
Primary purpose
OTHER

Primary Outcome Measure

Retinal thickness [ Time Frame: Interventional ]

Related Studies